Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study

Mauro G. Trovò, Emilio Minatel, Giovanni Franchin, Carlo Gobitti, Mario Roncadin, Antonino De Paoli, Mauro Arcicasa, Giovanni Boz, Roberto Bortolus

Research output: Contribution to journalArticlepeer-review

Abstract

From January 1984 to December 1986, 94 patients with unresectable, locally advanced, non-small cell lung cancer (NSCLC) were treated to assess both the efficacy and the toxicity of a combined modality treatment including radiation therapy (45 Gy/15 fractions/3 weeks) and daily low dose cDDP (6 mg/m2). The overall response rate for the 90 evaluable patients was 54.3% with 16.6% of complete responses. At a minimum follow-up of 4 years, the overall median survival time was 12 months. Provided adequate hydration is ensured, the cDDP regimen chosen as a radiosensitizer can be safely combined with radiation therapy.

Original languageEnglish
Pages (from-to)241-244
Number of pages4
JournalRadiotherapy and Oncology
Volume23
Issue number4
DOIs
Publication statusPublished - 1992

Keywords

  • cDDP
  • Non-small cell lung cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Urology

Fingerprint Dive into the research topics of 'Radiotherapy enhanced by cis-platinum in stage III non-small cell lung cancer: a phase II study'. Together they form a unique fingerprint.

Cite this